Q32 Bio enters ATM sales agreement for up to $14.2M common stock offering

Q32 Bio Inc.

Enters Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. for at-the-market sales.
May sell shares with aggregate offering price up to $14.2 million via prospectus supplement filed March 27, 2026.
Sales made on Nasdaq or other trading markets; Agent receives 3.0% cash commission on gross proceeds.
Company not obligated to sell any shares; can suspend or terminate offering on notice to Agent.
Uses existing shelf registration statement Form S-3 (File No. 333-286491) effective April 21, 2025.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Q32 Bio Inc. entered into Controlled Equity Offering SM Sales Agreement with Cantor Fitzgerald & Co. valued at up to $14,200,000 (effective 2026-03-27).

Action: entry
Agreement: atm program
Counterparty: Cantor Fitzgerald & Co.
Value: up to $14,200,000
Effective: 2026-03-27

Exact text from the filing

On March 27, 2026, Q32 Bio Inc. (the “Company”) entered into a Controlled Equity Offering SM Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. (the “Sales Agent”)

View on SEC.gov

299 material agreements filed in the last 30 days. Browse all material agreements →

Q32 Bio Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-129431

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.